These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30231344)

  • 1. Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Raj N; Fazio N; Strosberg J
    Am Soc Clin Oncol Educ Book; 2018 May; 38():292-299. PubMed ID: 30231344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
    Cives M; Strosberg J
    Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Strosberg JR
    CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
    Perez K; Chan J
    Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
    Garcia-Carbonero R
    Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
    [No Abstract]   [Full Text] [Related]  

  • 6. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Cloyd JM; Konda B; Shah MH; Pawlik TM
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
    Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
    Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Öberg K; Knigge U; Kwekkeboom D; Perren A;
    Ann Oncol; 2012 Oct; 23 Suppl 7():vii124-30. PubMed ID: 22997445
    [No Abstract]   [Full Text] [Related]  

  • 9. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].
    Luley K; Gebauer J; Gebauer N; Tharun L; Buchmann I; Barkhausen J; von Bubnoff N; Lindner K; Keck T; Lehnert H; Schmid SM
    Internist (Berl); 2020 Aug; 61(8):875-890. PubMed ID: 32676723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: Discussion.
    Iyer R; Phan AT; Boudreaux JP
    Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):18-19. PubMed ID: 28654026
    [No Abstract]   [Full Text] [Related]  

  • 11. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.
    Neychev V; Kebebew E
    Int J Surg Oncol; 2017; 2017():6424812. PubMed ID: 28593056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gastroenteropancreatic neuroendocrine tumor microenvironment and related therapy].
    Ye C; Yuan CH; Li G; Zheng L; Xiu DR
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):866-871. PubMed ID: 31694137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intervention in gastro-enteropancreatic neuroendocrine tumours.
    Baudin E; Planchard D; Scoazec JY; Guigay J; Dromain C; Hadoux J; Debaere T; Elias D; Ducreux M
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):855-65. PubMed ID: 23582924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT; Kunz PL; Reidy-Lagunes DL
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive gastro-entero-pancreatic neoplasms.
    Coriat R
    Ann Endocrinol (Paris); 2019 Jun; 80(3):185-186. PubMed ID: 31064660
    [No Abstract]   [Full Text] [Related]  

  • 17. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
    Bellizzi AM
    Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
    Karakuş E; Helvacı A; Ekinci O; Dursun A
    Turk J Gastroenterol; 2014 Feb; 25(1):81-7. PubMed ID: 24918137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Alexandraki KI; Karapanagioti A; Karoumpalis I; Boutzios G; Kaltsas GA
    Biomed Res Int; 2017; 2017():9856140. PubMed ID: 29349087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.